Summit Therapeutics PLC (SMMT)
NASDAQ:SMMT
Want to see SMMT full AI Analyst Report?
Top Page
Summit Therapeutics
(NASDAQ:SMMT)
Select Model
Select Model
Rating:52Neutral
Price Target:
$19.00
▼(-24.45% Downside)
Action:Reiterated
Date:05/02/26
The score is held back primarily by very weak financial performance (no revenue, widening losses, and substantial cash burn) and a technically weak price trend (below major moving averages). These are partially offset by a comparatively strong earnings-call backdrop featuring significant clinical/regulatory progress and a strong cash position with no debt, which improves near-term funding flexibility despite ongoing trial and approval risks.
Positive Factors
Strong cash position, no debt
A cash balance of ~$713M and zero debt materially extends runway for pivotal Phase III readouts, manufacturing validation and commercial prep. This reduces near-term financing pressure, allowing the company to fund trials and U.S. launch readiness over the next 2–6 months without immediate dilution risk.
Negative Factors
High cash burn and widening losses
Very large TTM losses and negative free cash flow reflect a stepped-up spending profile tied to late‑stage programs. Continued high burn will erode cash reserves absent milestone or commercial revenue, increasing the probability of future financing, dilution, or partnership dependence if approvals or payments lag.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong cash position, no debt
A cash balance of ~$713M and zero debt materially extends runway for pivotal Phase III readouts, manufacturing validation and commercial prep. This reduces near-term financing pressure, allowing the company to fund trials and U.S. launch readiness over the next 2–6 months without immediate dilution risk.
Read all positive factors
Summit Therapeutics (SMMT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$12.43B
Dividend YieldN/A
Average Volume (3M)4.31M
Price to Earnings (P/E)―
Beta (1Y)2.66
Revenue GrowthN/A
EPS Growth-384.68%
CountryUS
Employees159
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.40
Shares Outstanding776,162,660
10 Day Avg. Volume3,440,868
30 Day Avg. Volume4,305,194
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)26.74
Price to Sales (P/S)0.00
P/FCF Ratio-54.45
Enterprise Value/Market Cap1.11
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-13.02
Forecast
1Y Price Target
$30.83Price Target Upside22.60% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)-1.12
Revenue Forecast (FY)$7.25M
Summit Therapeutics Business Overview & Revenue Model
Company Description
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infect...
How the Company Makes Money
Summit Therapeutics primarily makes money through collaboration-related payments and other income associated with its licensing arrangements, rather than through product sales (as it is a clinical-stage company). A key driver is its partnership wi...
Summit Therapeutics Earnings Call Summary
Earnings Call Date:Feb 23, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:Aug 12, 2026
Earnings Call Sentiment Positive
The call presented a strong set of clinical and operational achievements: multiple positive Phase III readouts, broad global development, robust patient exposure, strategic collaborations, a healthy cash balance ($713.4M), manufacturing transfer to the U.S., and an accepted BLA with a November 14, 2026 PDUFA date. Key risks remain around demonstrating statistically significant overall survival for U.S. approval in the EGFR setting, OS immaturity at the interim PFS readout for HARMONi-3 squamous, increased near-term R&D spending (non-GAAP op expenses +~9.6% Q/Q), and reliance on partner-generated data from China which may require bridging for global regulatory bodies. On balance, the highlights (clinical momentum, approvals in China, partnerships, cash runway, manufacturing readiness) outweigh the challenges, but the path to full U.S. approval and broader commercialization depends on forthcoming OS data and regulatory interactions.Positive Updates
Strong cash position and no debt
Ended FY2025 with approximately $713.4 million in cash and no debt, supporting continued clinical development and commercial readiness activities.
Negative Updates
Regulatory requirement for overall survival in EGFR setting
FDA noted that a statistically significant overall survival (OS) benefit is necessary to support marketing authorization in the EGFR post-TKI setting; OS immaturity at interim PFS analyses means approval risk remains contingent on future OS data.
Read all updates
Q4-2025 Updates
Positive
Negative
Strong cash position and no debt
Ended FY2025 with approximately $713.4 million in cash and no debt, supporting continued clinical development and commercial readiness activities.
Read all positive updates
Company Guidance
Summit guided that an interim PFS analysis for the HARMONi‑3 squamous cohort will be conducted in Q2 2026 (squamous screening complete with ~600 patients randomized), with final PFS and an interim OS analysis planned in H2 2026; the non‑squamous cohort is expected to complete enrollment in H2 2026 and reach prespecified events for final PFS by H1 2027. The company reminded investors the HARMONi BLA is accepted by FDA with a PDUFA date of Nov 14, 2026 (FDA has indicated a statistically significant OS benefit will be required for approval in the EGFR‑mutant post‑TKI setting). Financial and operational metrics disclosed included cash of ~$713.4M at year‑end 2025 with no debt; Q4 2025 GAAP operating expenses of $225M (vs. $234.2M in Q3), non‑GAAP operating expenses of $113.3M (vs. $103.4M), a $19.1M decrease in stock‑based comp offset by an $8.8M increase in clinical spend, and full‑year 2025 G&A ex‑stock comp of ~$43M (run rate ~$10–11M/quarter). Pipeline and milestone metrics: 4 Phase III readouts to date (all positive), ~15 randomized Phase III trials announced/ongoing, 44 trials initiated since 2019, 142 total trials listed on ClinicalTrials.gov (including ISTs), >4,000 patients enrolled in Summit/Akeso trials, >60,000 patients treated commercially in China across two approved indications, ILLUMINE (GORTEC) Phase III to enroll ~780 patients beginning next quarter, Revolution collaboration first patient dosed, GSK combo study to begin dosing mid‑2026, and production process successfully transferred and validated to a U.S. manufacturer.Summit Therapeutics Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
63
Positive
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 583.19K | 1.34M |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 583.19K | 1.34M |
| EBITDA | -1.06B | -1.08B | -168.46M | -69.45M | -51.58M | -62.74M |
| Net Income | -1.05B | -1.08B | -176.77M | -482.37M | -65.17M | -65.52M |
Balance Sheet | ||||||
| Total Assets | 491.31M | 557.50M | 348.05M | 160.60M | 541.43M | 84.04M |
| Cash, Cash Equivalents and Short-Term Investments | 454.05M | 529.49M | 329.50M | 147.38M | 284.18M | 53.22M |
| Total Debt | 15.20M | 15.50M | 5.77M | 83.96M | 422.89M | 2.06M |
| Total Liabilities | 77.30M | 68.52M | 37.41M | 99.12M | 438.18M | 22.30M |
| Stockholders Equity | 414.01M | 488.98M | 310.64M | 61.48M | 103.25M | 61.74M |
Cash Flow | ||||||
| Free Cash Flow | -286.92M | -240.15M | -113.67M | -60.85M | -34.41M | -54.03M |
| Operating Cash Flow | -286.56M | -239.67M | -113.56M | -60.74M | -33.90M | -53.81M |
| Investing Cash Flow | -249.64M | -129.37M | -164.09M | -465.14M | -508.68K | -226.83K |
| Financing Cash Flow | 455.51M | 458.31M | 304.63M | 68.46M | 505.62M | 57.76M |
Summit Therapeutics Technical Analysis
Negative
25.15
Price Trends
18.81
Negative
17.54
Negative
19.14
Negative
Market Momentum
-0.87
Positive
36.44
Neutral
10.36
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SMMT, the sentiment is Negative. The current price of 25.15 is above the 20-day moving average (MA) of 19.08, above the 50-day MA of 18.81, and above the 200-day MA of 19.14, indicating a bearish trend. The MACD of -0.87 indicates Positive momentum. The RSI at 36.44 is Neutral, neither overbought nor oversold. The STOCH value of 10.36 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SMMT.
Summit Therapeutics Risk Analysis
Summit Therapeutics disclosed 71 risk factors in its most recent earnings report. Summit Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Summit Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
81 Outperform | $19.02B | 15.46 | 29.31% | ― | 21.48% | 1853.63% | |
79 Outperform | $24.07B | 23.46 | 19.24% | ― | 5.87% | 8.18% | |
63 Neutral | $15.67B | 77.40 | 20.51% | ― | 21.02% | -24.83% | |
62 Neutral | $14.82B | 4.77 | -5641.90% | ― | 155.14% | ― | |
55 Neutral | $22.47B | -8.99 | -6.67% | ― | 10.01% | -71.78% | |
52 Neutral | $12.43B | -19.40 | -340.55% | ― | ― | -384.68% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
SMMT
Summit Therapeutics
15.85
-9.56
-37.62%
INCY
Incyte
95.60
30.82
47.58%
UTHR
United Therapeutics
566.80
257.12
83.03%
ASND
Ascendis Pharma
237.98
79.88
50.52%
GMAB
Genmab
25.68
5.16
25.15%
BNTX
BioNTech SE
87.79
-11.30
-11.40%
Summit Therapeutics Corporate Events
Business Operations and StrategyFinancial DisclosuresRegulatory Filings and Compliance
Summit Therapeutics Reports 2025 Results, Advances Ivonescimab Programs
Positive
Feb 23, 2026
On February 23, 2026, Summit Therapeutics reported its fourth-quarter and full-year 2025 results, highlighting rapid advancement of ivonescimab across a broad Phase III oncology program and multiple collaborations. The company’s global HARMO...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.